A case of fulminant demyelinating disease associated with golimumab treatment

A case of fulminant demyelinating disease associated with golimumab treatment

•Tumour necrosis factor alpha inhibitors are widely used in the treatment of inflammatory diseases.•Clinical trials investigating the therapeutic effects of TNF-α inhibitors in MS have failed.•TNF-α inhibitors may trigger the emergence of demyelinating events in susceptible individuals.•Only one cas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical neurology and neurosurgery 2020-08, Vol.195, p.105887-105887, Article 105887
Hauptverfasser: Yetkin, Mehmet Fatih, Kendirci, Murat, İsmailoğullari, Sevda, Gültekin, Murat, Baydemir, Recep, Sarilar, Ayşe Çağlar, Köse, Elif Gülşen, Akcakoyunlu, Merve, Erbay, Ülfet Zehra, Erol, Kemal, Ketenci Ertaş, Şule, Şenel, Soner, Mirza, Meral
Format: Artikel
Sprache:eng
Schlagworte:
Animal models
Back pain
Demyelinating diseases
Demyelination
Disease
Family medical history
Medical prognosis
Monoclonal antibodies
Multiple sclerosis
Nervous system
Neurology
Pathogenesis
Patients
Rheumatology
TNF inhibitors
Tumor necrosis factor-α
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Tumour necrosis factor alpha inhibitors are widely used in the treatment of inflammatory diseases.•Clinical trials investigating the therapeutic effects of TNF-α inhibitors in MS have failed.•TNF-α inhibitors may trigger the emergence of demyelinating events in susceptible individuals.•Only one case of CNS demyelination associated with golimumab has been previously reported.•Long-term immunomodulatory therapy may be considered in selected patients.
ISSN:0303-8467
1872-6968
DOI:10.1016/j.clineuro.2020.105887